Recent advances on smart glycoconjugate vaccines in infections and cancer

Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor-associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy

Hydrothermal carbonization of spent mushroom substrate: Physicochemical characterization, combustion behavior, kinetic and thermodynamic study

Hydrothermal carbonization (HTC) was employed for the conversion of the spent mushroom substrate (SMS) into a carbonaceous hydrochar. The effect of operating temperature (180, 200, 220, 240, and 260 ?C) on the physicochemical, structural, and combustion properties of the obtained hydrochars was analyzed. The HTC treatment caused the increase of the higher heating value (HHV) and the lower heating value (LHV) of hydrochars for 58 % and 65 % in comparison with SMS, respectively. Analysis of morphology and functional groups showed the formation of microspheres and cracks on the hydrochar surface, which are predominantly dominated by aromatic and oxygen-rich functional groups. Thermal and kinetics analysis showed that HTC treatment improves the combustion behavior of the obtained solids. Combustion kinetic parameters of SMS and hydrochars were determined by the methods of Kissenger-Akahira-Sunose (KAS) and Flynn-Wall-Ozawa (FWO). The thermodynamic parameters and pre-exponential factors reveal a complex mechanism of SMS and hydrochars decomposition process

Emerging glyco-based strategies to steer immune responses

Glycan structures are common posttranslational modifications of proteins, which serve multiple important structural roles (for instance in protein folding), but also are crucial participants in cell–cell communications and in the regulation of immune responses. Through the interaction with glycan-binding receptors, glycans are able to affect the activation status of antigen-presenting cells, leading either to induction of pro-inflammatory responses or to suppression of immunity and instigation of immune tolerance. This unique feature of glycans has attracted the interest and spurred collaborations of glyco-chemists and glyco-immunologists to develop glycan-based tools as potential therapeutic approaches in the fight against diseases such as cancer and autoimmune conditions. In this review, we highlight emerging advances in this field, and in particular, we discuss on how glycan-modified conjugates or glycoengineered cells can be employed as targeting devices to direct tumor antigens to lectin receptors on antigen-presenting cells, like dendritic cells. In addition, we address how glycan-based nanoparticles can act as delivery platforms to enhance immune responses. Finally, we discuss some of the latest developments in glycan-based therapies, including chimeric antigen receptor (CAR)-T cells to achieve targeting of tumor-associated glycan-specific epitopes, as well as the use of glycan moieties to suppress ongoing immune responses, especially in the context of autoimmunity

Recent advances on smart glycoconjugate vaccines in infections and cancer

Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor-associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy

Conductive Polypyrrole/Tungsten Oxide Metacomposites with Negative Permittivity

Polypyrrole (PPy) nanocomposites reinforced with tungsten oxide (WO 3) nanoparticles (NPs) and nanorods (NRs) are fabricated by a surface-initiated polymerization method. The electrical conductivity is observed to depend strongly on the particle loadings, molar ratio of oxidant to pyrrole monomer, and the filler morphology. The electron transportation in the nanocomposites follows a quasi-three-dimensional variable range hopping (VRH) conduction mechanism as evidenced by the temperature-dependent conductivity function. Unique negative permittivity is observed in both pure PPy and its nanocomposites, and the switching frequency (frequency where the real permittivity switches from negative to positive) can be tuned by changing the particle loading, ratio of oxidant to pyrrole monomer, and the filler morphology. The extent of charge carrier localization calculated from the VRH mechanism is well-correlated to the dielectric properties of the nanocomposites. WO3 NRs are observed to be more efficient in improving the electrical conductivity, dielectric permittivity, and thermal stability of the resulting nanocomposites as compared to those with WO3 NPs. The microstructures of pure PPy and its nanocomposites are observed by scanning electron microscopy and transmission electron microscopy. Powder X-ray diffraction analysis demonstrates the crystalline structure of WO3 nanostructures, as well as their corresponding nanocomposites. Thermogravimetric analysis reveals a significantly enhanced thermal stability with the addition of nanofillers. © 2010 American Chemical Society